Protagonist Therapeutics PRXNA Bond

PTGX Stock  USD 45.53  0.93  2.00%   
Protagonist Therapeutics holds a debt-to-equity ratio of 0.017. At this time, Protagonist Therapeutics' Long Term Debt is fairly stable compared to the past year. Short Term Debt is likely to rise to about 3.1 M in 2024, despite the fact that Net Debt is likely to grow to (176.3 M). With a high degree of financial leverage come high-interest payments, which usually reduce Protagonist Therapeutics' Earnings Per Share (EPS).

Asset vs Debt

Equity vs Debt

Protagonist Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Protagonist Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Protagonist Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Protagonist Therapeutics' stakeholders.
For most companies, including Protagonist Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Protagonist Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Protagonist Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
5.2056
Book Value
8.936
Operating Margin
(8.87)
Profit Margin
0.5277
Return On Assets
0.1996
At this time, Protagonist Therapeutics' Total Current Liabilities is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 375.8 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 209.9 K in 2024.
  
Check out the analysis of Protagonist Therapeutics Fundamentals Over Time.
For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.
View Bond Profile
Given the importance of Protagonist Therapeutics' capital structure, the first step in the capital decision process is for the management of Protagonist Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Protagonist Therapeutics to issue bonds at a reasonable cost.
Popular NameProtagonist Therapeutics PRXNA 3832 08 FEB 51
SpecializationPharmaceuticals, Biotechnology & Life Sciences
Equity ISIN CodeUS74366E1029
Bond Issue ISIN CodeUS74365PAE88
S&P Rating
Others
Maturity DateOthers
Issuance DateOthers
View All Protagonist Therapeutics Outstanding Bonds

Protagonist Therapeutics Outstanding Bond Obligations

Understaning Protagonist Therapeutics Use of Financial Leverage

Understanding the structure of Protagonist Therapeutics' debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Protagonist Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last ReportedProjected for Next Year
Net Debt-185.6 M-176.3 M
Long Term Debt11.3 M11.8 M
Long Term Debt Total11.3 M6.6 M
Short Term Debt2.3 M3.1 M
Short and Long Term Debt Total1.1 M1.1 M
Net Debt To EBITDA 2.05  1.03 
Interest Debt Per Share 0.02  0.02 
Long Term Debt To Capitalization(0.04)(0.04)
Cash Flow To Debt Ratio(61.56)(64.63)
Please read more on our technical analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagonist Stock Analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.